8-K: QHSLab Repurchases Debt, Boosts Capital Structure

QHSLab, Inc. announced the repurchase and retirement of over $1.4 million in legacy convertible debt for $300,000, significantly strengthening its balance sheet and reducing future dilution.

Summary

• QHSLab, Inc. completed a Note Repurchase Agreement on November 18, 2025, to buy back outstanding convertible promissory notes.
• The notes, originally issued in August 2021 and July 2022, were in default and carried an 18% default interest rate.
• The aggregate outstanding balance of the notes, including principal and accrued interest, exceeded $1.4 million.
• QHSLab repurchased these notes for a cash payment of $300,000, funded by company operations and a short-term advance from the CEO.
• The repurchase extinguished all obligations, conversion rights (at $0.20 per share), security interests, liens, and claims related to the notes.
• The company reported Q3 2025 revenue of $737,066, a 35% increase year-over-year, and a gross profit of $493,631, also up 35%.
• Year-to-date 2025 revenue reached $1.99 million, a 32% increase from the prior year, with a gross profit of $1.32 million (66% gross margin).
• Q3 2025 net income was $33,411, while year-to-date 2025 saw a net loss of ($99,156).
• The repurchase eliminates over $200,000 in annualized interest expense and several million shares of potential dilution.
• As of November 20, 2025, the Company had 11,281,527 common shares outstanding.

Sentiment

Score: 8

Explanation: The debt repurchase at a significant discount, coupled with strong revenue and gross profit growth, substantially improves the company's financial health and future prospects by reducing debt, interest expense, and dilution risk. While there was a YTD net loss, the strategic financial move and operational momentum are highly positive.

Positives

• Repurchased over $1.4 million in defaulted convertible debt for $300,000, a significant discount.
• Eliminates an 18% default interest rate and over $200,000 in annualized interest expense.
• Removes a significant conversion overhang and the risk of several million shares of future dilution at a $0.20 conversion price.
• Strengthens the company's balance sheet and capital structure.
• Reported robust Q3 2025 revenue of $737,066, a 35% increase compared to Q3 2024.
• Gross profit for Q3 2025 increased by 35% to $493,631, maintaining a strong gross margin of 67%.
• Operating income for Q3 2025 increased to $96,251 from $89,090 in Q3 2024.
• Year-to-date 2025 revenue grew 32% to $1.99 million.
• Year-to-date 2025 gross profit increased to $1.32 million with an improved gross margin of 66% from 63% a year ago.
• Cash and cash equivalents remained steady at $158,391 at September 30, 2025, compared to $157,168 at December 31, 2024.
• Continued deployment of the ISP platform is increasing recurring SaaS and service revenue.
• Ongoing R&D spending of $132,769 in Q3 2025 supports product innovation and enhancements.

Negatives

• The company incurred a net loss of ($99,156) for the first nine months of 2025, compared to a net income of $28,350 for the same period in 2024.
• Operating expenses increased to $1.23 million year-to-date 2025 from $0.81 million in 2024, driven by investment in product development and market expansion.
• Net income for Q3 2025 decreased to $33,411 from $49,765 in Q3 2024.
• The notes were in default, indicating prior financial distress.

Risks

• Forward-looking statements are subject to numerous risks and uncertainties, including the timing of new product introductions, discrepancies between actual results and management estimates, regulatory delays, changes in government funding and budgets, and general economic conditions.
• The company previously had convertible notes in default, indicating past financial challenges.
• Increased operating expenses due to investment in product development and market expansion could impact profitability if revenue growth does not keep pace.
• The company experienced a net loss year-to-date 2025, which could continue if growth initiatives do not yield sufficient returns.

Future Outlook

Looking ahead to 2026, QHSLab remains focused on advancing its digital medicine ecosystem, strengthening relationships with primary-care providers, and expanding collaborations with behavioral health groups. The company plans to pursue new opportunities in population health, cognitive assessment, allergy diagnostics, and preventive care, with priorities including growing recurring revenues, improving cash flow, and leveraging strategic partnerships to achieve long-term, sustainable profitability.

Management Comments

• "Through the first nine months of 2025, we continued to demonstrate strong operational momentum and revenue growth across our digital health and integrated service program."
• "Our 35 percent year-over-year revenue increase in the third quarter reflects the effectiveness of our technology, the engagement of our physician customers, and the scalability of our solutions within primary care settings."
• "The repurchase of our legacy convertible notes is another important step forward. Eliminating over $1.4 million in defaulted debt obligations significantly strengthens our balance sheet, reduces interest expense going forward, and removes a large conversion overhang that posed a significant dilution risk to our shareholders."
• "This action positions QHSLab for a healthier financial trajectory as we plan our next phase of growth."
• "With a cleaner capital structure and stronger financial footing following the retirement of our legacy debt, we believe QHSLab is well-positioned to expand its market presence and deliver lasting value for our shareholders."

Industry Context

The digital health and medical device industry continues to see strong demand for solutions that enable primary care physicians to deliver value-based chronic disease and preventive care services. QHSLab's focus on expanding its ISP platform and investing in product innovation for cognitive screening and psychosocial risk tools aligns with broader industry trends towards integrated, technology-driven healthcare solutions. The company's ability to grow recurring SaaS and service revenue indicates successful penetration in a competitive market, while the debt repurchase improves its financial standing to better compete and invest in future growth within this evolving sector.

Related Party Transactions

• A short-term advance was provided by the Company's President and Chief Executive Officer to fund a portion of the Repurchase Price.

Stakeholder Impact

• Shareholders: Significant positive impact due to reduced dilution risk (elimination of conversion rights at $0.20/share), strengthened balance sheet, and reduced future interest expense, potentially leading to increased shareholder value.
• Creditors: The former noteholder received $300,000 in cash for notes with an aggregate balance exceeding $1.4 million, implying a significant haircut but full satisfaction of the debt.
• Employees: Continued investment in product development and market expansion suggests stability and potential growth opportunities.
• Customers (Physicians/Practices): Continued deployment of the ISP platform and product innovation (Q-Cog, Q-Scale) indicates ongoing commitment to enhancing service offerings.

Next Steps

• Advance the digital medicine ecosystem.
• Strengthen relationships with primary-care providers.
• Expand collaborative efforts with behavioral health groups.
• Pursue new opportunities in population health, cognitive assessment, allergy diagnostics, and preventive care.
• Grow recurring revenues.
• Improve cash flow.
• Leverage strategic partnerships to support long-term, sustainable profitability.

Key Dates

Recommendation

The repurchase of over $1.4 million in defaulted convertible debt for a mere $300,000 is an exceptionally accretive event, immediately improving the balance sheet, eliminating significant interest expense, and removing a substantial dilution overhang. This strategic move, combined with robust Q3 2025 revenue growth of 35% and strong gross margins, positions QHSLab for a healthier financial trajectory and future profitability. Despite a year-to-date net loss, the fundamental improvements in capital structure and operational momentum suggest a strong upside potential for the stock, making it a compelling 'strong buy' for investors looking for a company with significantly de-risked financials and clear growth drivers in the digital health sector.

Keywords

QHSLab, USAQ, debt repurchase, convertible notes, capital structure, balance sheet, dilution reduction, digital health, medical device, Q3 2025 earnings, revenue growth, gross profit, operating income, net income, SaaS revenue, chronic disease management, preventive care, SEC filing, 8-K